Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-18T16:08:06.446Z Has data issue: false hasContentIssue false
  • English
  • Français

Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma

Published online by Cambridge University Press:  07 August 2017

Ilaria Bini ,
Sebastian D. Asaftei ,
Chiara Riggi ,
Elisa Tirtei ,
Rosaria Manicone ,
Eleonora Biasin ,
Maria Eleonora Basso ,
Gabriella Agnoletti  and
Franca Fagioli
Ilaria Bini*
Affiliation:
Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Torino, Italy
Sebastian D. Asaftei
Affiliation:
Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Torino, Italy
Chiara Riggi
Affiliation:
Cardiology Department, Regina Margherita Children’s Hospital, Torino, Italy
Elisa Tirtei
Affiliation:
Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Torino, Italy
Rosaria Manicone
Affiliation:
Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Torino, Italy
Eleonora Biasin
Affiliation:
Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Torino, Italy
Maria Eleonora Basso
Affiliation:
Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Torino, Italy
Gabriella Agnoletti
Affiliation:
Cardiology Department, Regina Margherita Children’s Hospital, Torino, Italy
Franca Fagioli
Affiliation:
Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Torino, Italy
*
Correspondence to: I. Bini, MD, Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Piazza Polonia 94, 10126 Torino, Italy. Tel: +39 011 313 5200; Fax: +39 011 313 5487; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

Anthracycline cardiotoxicity is an important side-effect in long-term childhood cancer survivors. We evaluated the incidence of and factors associated with anthracycline cardiotoxicity in a population of patients diagnosed with bone or soft tissue sarcoma.

Materials and methods

We retrospectively enrolled patients diagnosed with bone or soft tissue sarcoma, from 1995 to 2011, treated with anthracycline chemotherapy at our Centre and with a follow-up echocardiography carried out ⩾3 years from cardiotoxic therapy completion. Cardiac toxicity was graded using Common Terminology Criteria for Adverse Events version 4.0.

Results

A total of 82 patients were eligible. The median age at treatment was 11.9 years (1.44–18). We evaluated the median cumulative anthracycline dose, age at treatment, sex, thoracic radiotherapy, hematopoietic stem cell transplantation, and high-dose cyclophosphamide treatment as possible risk factors for cardiotoxicity. The median cumulative anthracycline dose was 390.75 mg/m2 (80–580). Of the 82 patients, 12 (14.6%) developed cardiotoxicity with grade ⩾2 ejection fraction decline: four patients were asymptomatic and did not receive any treatment; six patients were treated with pharmacological heart failure therapy; one patient with severe cardiomyopathy underwent heart transplantation and did not need any further treatment; and one patient died while waiting for heart transplantation. The median time at cardiac toxicity, from the end of anthracycline frontline chemotherapy, was 4.2 years (0.05–9.6). Cumulative anthracycline dose ⩾300 mg/m2 (p 0.04) was the only risk factor for cardiotoxicity on statistical analyses.

Conclusions

In our population, the cumulative incidence of cardiotoxicity is comparable to rates in the literature. This underlines the need for primary prevention and lifelong cardiac toxicity surveillance programmes in long-term childhood cancer survivors.

Keywords

Anthracyclinecardiotoxicitychildren cancer survivorsbone sarcomasoft tissue sarcoma
Type
Original Articles
Information
Cardiology in the Young , Volume 27 , Issue 9 , November 2017 , pp. 1815 - 1822
Check for updates
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl 3): iii113–iii123.Google Scholar
2. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl 3): iii102–iii112.Google Scholar
3. Gaspar, N, Hawkins, DS, Dirksen, U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 2015; 33: 3036–3046.Google Scholar
4. Oeffinger, KC, Mertens, AC, Sklar, CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572–1582.Google Scholar
5. Mulrooney, DA, Yeazel, MW, Kawashima, T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339: b4606.Google Scholar
6. Mulrooney, DA, Armstrong, GT, Huang, S, et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: a cross-sectional study. Ann Intern Med 2016; 164: 93–101.CrossRefGoogle ScholarPubMed
7. Brown, TR, Vijarnsorn, C, Potts, J, Milner, R, Sandor, GG, Fryer, C. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study. Pediatr Blood Cancer 2013; 60: 842–848.Google Scholar
8. Longhi, A, Ferrari, S, Tamburini, A, et al. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Cancer 2012; 118: 5050–5059.Google Scholar
9. Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancer, version 4.0, 2013. Retrieved July 19, 2017, from http://www.survivorshipguidelines.org/pdf/LTFUGuidelines_40.pdf.Google Scholar
10. Armenian, SH, Hudson, MM, Mulder, RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015; 16: e123–e136.Google Scholar
11. Lipshultz, SE, Franco, VI, Miller, TL, Colan, SD, Sallan, SE. Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med 2015; 66: 161–176.CrossRefGoogle ScholarPubMed
12. Kremer, LC, Van Dalen, EC, Offringa, M, et al. Frequency and risk factors of anthracycline induced clinical heart failure in children: a systematic review. Ann Oncol 2002; 13: 503–512.Google Scholar
13. Ehrhardt, MJ, Fulbright, JM, Armenian, SH. Cardiomyopathy in childhood cancer survivors: lessons from the past and challenges for the future. Curr Oncol Rep 2016; 18: 22.Google Scholar
14. Armstrong, GT, Kawashima, T, Leisenring, W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014; 32: 1218–1227.Google Scholar
15. Lipshultz, SE, Miller, TL, Lipsitz, SR, et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 2012; 130: 1003–1011.Google Scholar
16. Lipshultz, SE, Giantris, AL, Lipsitz, SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 2002; 20: 1677–1682.Google Scholar
17. Lipshultz, SE, Lipsitz, SR, Orav, EJ. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: a claim without compelling evidence. J Clin Oncol 2007; 25: 3179, author reply 3180.CrossRefGoogle ScholarPubMed
18. Hellmann, K. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: a claim without evidence. J Clin Oncol 2007; 25: 4689–4690; author reply 90–91.Google Scholar
19. Asselin, B, Devidas, M, Zhou, T. Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL). J Clin Oncol 2012; 30 (Suppl): 9504.Google Scholar
20. Kopp, LM, Bernstein, ML, Schwartz, CL. The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS). J Clin Oncol 2012; 30 (Suppl): 9503.Google Scholar
21. Barry, EV, Vrooman, LM, Dahlberg, SE. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008; 26: 1106–1111.CrossRefGoogle ScholarPubMed
22. Barry, EV, Vrooman, LM, Dahlberg, SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008; 26: 1106–1111.Google Scholar
23. Lipshultz, SE, Scully, RE, Lipsitz, SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11: 950–961.Google Scholar
24. Lipshultz, SE, Franco, VI, Sallan, SE, et al. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence. Prog Pediatr Cardiol 2014; 36: 39–49.Google Scholar
25. Ebb, D, Meyers, P, Grier, H, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol 2012; 30: 2545–2551.CrossRefGoogle ScholarPubMed
26. Kopp, LM, Bernstein, ML, Schwartz, CL. The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS). J Clin Oncol 2012; 30 (Suppl): 9503.Google Scholar
27. US Food and Drug Administration. Orphan drug designations and approvals. Retrieved July 19, 2017, from https://www.accessdata.fda.gov/scripts/opdlisting/oopd/.Google Scholar
28. Agenzia Italiana del Farmaco (AIFA). Nota informativa su Cardioxane (dexrazoxano) del 18 luglio, 2011.Google Scholar
29. Smith, LA, Cornelius, VR, Plummer, CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10: 337.CrossRefGoogle ScholarPubMed
30. De Sanctis, R, Bertuzzi, A, Basso, U, et al. Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. Anticancer Res 2015; 35: 543–547.Google ScholarPubMed
31. Judson, I, Radford, JA, Harris, M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELIX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37: 870–877.CrossRefGoogle ScholarPubMed
32. van Dalen, EC, Michiels, EM, Caron, HN, Kremer, LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010; 5: CD005006.Google Scholar
33. Creutzig, U, Zimmermann, M, Bourquin, JP, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013; 122: 37–43.Google Scholar
34. Muñoz, A, Maldonado, M, Pardo, N, Fernández, JM, Vela, E, Cubells, J. Pegylated liposomal doxorubicin hydrochloride (PLD) for advanced sarcomas in children: preliminary results. Pediatr Blood Cancer 2004; 43: 152–155.CrossRefGoogle ScholarPubMed
35. Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors (NCT00019630). Retrieved July 19, 2017, from https://clinicaltrials.gov/ct2/show/NCT00019630.Google Scholar
36. A Phase I Study of Lyso-Thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults (NCT02536183). Retrieved July 19, 2017, from https://clinicaltrials.gov/ct2/show/NCT02536183.Google Scholar
37. Ghigo, A, Li, M, Hirsch, E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta 2016; 1863 (7 Pt B): 1916–1925.Google Scholar
38 Silber, JH, Cnaan, A, Clark, BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22: 820–828.Google Scholar
39. Lipshultz, SE, Lipsitz, SR, Sallan, SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20: 4517–4522.CrossRefGoogle ScholarPubMed
40. Kremer, LC, van Dalen, EC, Offringa, M, Ottenkamp, J, Voûte, PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 191–196.CrossRefGoogle Scholar